Using pyrosequencing to quantify the relative degree of DNA methylation, we found that CDH3 showed a substantial degree of methylation in the majority of kidney cancer cell lines, including A498 (relative methylation: 90%), 786-O (55%), RCC-GS (90%), and RCC-MF (65%); in one of two prostate cancer cell lines (LN-cap); and in two of seven bladder cancer cell lines (T24 and EJ28); while low methylation levels were found in primary cells used as normal tissue surrogate models (Figure 6). Here, CDH3 is linked to urinary bladder cancer.